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It has  been  increasingly  appreciated  that  tumor  necrosis  factor (TNF)  performs  various  protective  and
anti-inﬂammatory  functions  in  multiple  sclerosis  (MS)  and  its  animal  model  experimental  autoimmune
encephalomyelitis  (EAE).  Recently,  CXCL12  has  been  identiﬁed  as a key  inhibitor  of  leukocyte  entry  into
the  central  nervous  system  (CNS)  and  as  a regulator  of  inﬂammation  resulting  from  the  invasion.  Here, a
positive  correlation  between  expression  of TNF and  CXCL12  in  the  CNS  samples  of  EAE rats  is  presented.eywords:
xperimental autoimmune
ncephalomyelitis
umor necrosis factor
strocyte
XCL12
Also,  it is  shown  that  TNF  potentiates  CXCL12  expression  in astrocytes.  These  results  contribute  to  a  view
that  TNF  produced  within  the  CNS  plays  a protective  role  in neuroinﬂammation.
©  2015  Elsevier  GmbH.  All  rights  reserved.euroinﬂammation
ntroduction
Autoimmune response against the central nervous system (CNS)
lays a dominant role in pathogenesis of a chronic inﬂamma-
ory and demyelinating disease multiple sclerosis (MS) and its
nimal model experimental autoimmune encephalomyelitis (EAE)
Sospedra and Martin, 2005). Autoreactive CD4+ T lymphocytes
T helper, Th) of Th1 and Th17 phenotype are major pathogenic
ells in MS  and EAE (Petermann and Korn, 2011), while various
opulations of immune cells and CNS-resident cells contribute to
Abbreviations: AO, Albino Oxford; c.s., clinical score; CFA, complete Freund’s
djuvant; CNS, central nervous system; d.p.i., days post immunization; DA, Dark
gouti; DLN, draining lymph node; DLNC, draining lymph node cells; EAE, exper-
mental autoimmune encephalomyelitis; FCS, fetal calf serum; IFN, interferon; IL,
nterleukin; MBP, myelin basic protein; MS,  multiple sclerosis; PBMC, peripheral
lood mononuclear cells; PBS, phosphate buffer saline; PCR, polymerase chain reac-
ion; RDV, relative densitometry values; RT, reverse transcription; SC, spinal cord;
CH, spinal cord homogenate; SD, standard deviation; SDS, sodium dodecyl sulfate;
GF, transforming growth factor; Th, helper T cells; TNF, tumor necrosis factor; TNFR,
NF receptor.
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171-2985/© 2015 Elsevier GmbH. All rights reserved.the pathogenesis through divergent effector mechanisms including
cytokine generation (Sospedra and Martin, 2005). Tumor necro-
sis factor (TNF) is a pluripotent cytokine that mediates deleterious
inﬂammatory effects on the CNS tissue, but that also contributes to
neuroprotection and remyelination in MS  and EAE (Taouﬁk et al.,
2008). Such pluripotency seems to stem from different activities
of soluble form (sTNF) and transmembrane form (tmTNF) of the
cytokine, as well as from functional diversity of its receptors TNFRI
and TNFRII. TNF was detected in the inﬂamed CNS of MS patients,
both in immune cells and in nonhematopoietic cells (Hofman et al.,
1989; Selmaj et al., 1991). Its levels in CSF of MS  patients corre-
late with the disease activity and blood–brain barrier disruption
(Sharief and Thompson, 1992; Drulovic´ et al., 1997) and it has
recently been implied that TNF causes excitotoxic neurodegenera-
tion in primary progressive MS  (Rossi et al., 2014). Still, treatment
of MS  patients with lenercept (TNFRI fusion protein) or inﬂiximab
(anti-TNF antibody) led to exacerbation of the disease in clinical
trials (reviewed in Dendrou et al., 2013). Also, anti-TNF treatment
of patients with rheumatoid arthritis, Crohn’s disease and psoria-
sis has been repeatedly associated with demyelination and other
neurological adverse events (Kaltsonoudis et al., 2014). Finally, it
has recently been shown that a single nucleotide polymorphism
(rs1800693) in TNFR1 gene that leads to formation of soluble, i.e.
blocking, TNFR1 is a genetic risk for MS  (Gregory et al., 2012). Thus,
while it is clear that TNF has a dual role in MS  pathogenesis, its
disease-promoting and beneﬁcial effects in MS  are still uncom-
pletely understood.
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Comparison of autoimmune reaction directed against the CNS
n Albino Oxford (AO) and Dark Agouti (DA) rats that are at the
pposite poles of susceptibility to EAE induction has been a valu-
ble tool for studying neuroinﬂammation (Momcilovic´ et al., 2012).
O rats are almost completely resistant to EAE induction as they
o not express clinical signs of EAE in response to harsh immu-
ization protocols that are efﬁcient in other relatively resistant
at strains (Miljkovic et al., 2006). On the contrary, DA rats readily
evelop clinically manifested EAE even if subjected to mild immu-
ization, e.g. immunization without an adjuvant (Stosic-Grujicic
t al., 2004). The comparison of these two strains of rats has recently
llowed us to demonstrate an importance of a chemokine CXCL12
or regulation of neuroinﬂammation (Miljkovic´ et al., 2011a) in
greement with reports from other groups that indicate important
ole of CXCL12 in MS  pathogenesis. Namely, it was reported that
XCL12 prevents leukocyte migration into the CNS and that it pro-
otes immunoregulatory mechanisms within the CNS (reviewed
n Momcilovic´ et al., 2012). Astrocytes play important role in
S and EAE pathogenesis. These cells are major components of
lood–brain barrier, they are potential antigen-presenting cells and
hey are able to produce various anti- and pro-inﬂammatory sol-
ble mediators, including cytokines and chemokines (Miljkovic´
t al., 2011b). Notably, astrocytes are among the most promi-
ent producers of CXCL12 in the inﬂamed CNS (Ambrosini et al.,
005).
Here, kinetics of TNF expression in rat EAE is studied and strong
ositive correlation between expression of TNF and CXCL12 in the
NS of EAE rats is determined. It is demonstrated that TNF stimu-
ates CXCL12 expression in astrocytes.
aterials and methods
xperimental animals, EAE induction and evaluation
AO and DA rats – 2–3 months of age, sex matched in each exper-
ment – were maintained in the animal facility of the Institute for
iological Research “Sinisa Stankovic”. Animal experiments were
pproved by the local ethics committee (Institute for Biological
esearch “Sinisa Stankovic”, No. 2-22/10). EAE was induced with
at spinal cord homogenate (SCH) in phosphate buffer saline (PBS,
0%, w/v) mixed with equal volume of complete Freund’s adjuvant
CFA, Difco, Detroit, MI). The animals were injected, as previously
escribed (Miljkovic´ et al., 2011a). The rats were monitored daily
or clinical signs (c.s.) of EAE, and scored according to the following
cale: 0, no clinical signs; 1, ﬂaccid tail; 2, hind limb paresis; 3, hind
imb paralysis; 4, moribund state or death. DA rats had EAE onset
n 9–11 days post immunization (d.p.i) (c.s. 1), peak on 12–14 d.p.i.
c.s. 2–4) and recovery on 18–22 d.p.i. (c.s. 1 or less).
solation of cells, cell culturing and generation of supernatants
Rats were extensively perfused with cold PBS through left ven-
ricle before spinal cord isolation and homogenization. Spinal cords
ere homogenized by passing the tissue through 40-m stain-
ess steel mesh in 5 ml  PBS on ice. 50 l of homogenate samples
ere taken for RNA isolation and the rest of homogenates was  cen-
rifuged (100 g, 10 min, +4 ◦C) and the pellet was resuspended in
 ml  of 30% Percoll (Sigma–Aldrich, St. Louis, MO)  and overlaid on
 ml  of 70% Percoll gradient. Following centrifugation at 870 g for
0 min  the cells were recovered from the 30%/70% Percoll interface
nd washed in RPMI medium (PAA Laboratories, Pasching, Austria).
fterwards, so obtained immune cells (isolates) were kept on ice
ntil counted and used for RNA isolation or cell culturing. Isolates
ere seeded at 2.5 × 106/ml  of 24-well plates (Sarstedt, Nüm-
recht, Germany). Alternatively, spinal cord homogenates weregy 220 (2015) 845–850
centrifuged at 12,000 × g for 20 min  at 4 ◦C and supernatants were
collected for detection of TNF. CD4+ T cells were puriﬁed from the
isolates using biotin conjugated antibody speciﬁc for CD4 (eBio-
science, San Diego, CA) and IMag SAv particles plus (BD Biosciences,
San Diego, CA). Obtained purity of CD4+ T cells was more than
97% as determined by ﬂow cytometry. Spleens were isolated from
untreated DA rats and mechanically disrupted, passed through
40-m nylon mesh ﬁlter and the resulting suspension was col-
lected by centrifugation. Spleen cells (5 × 106/ml) were stimulated
with concanavalin A (ConA, Sigma–Aldrich, 5 mg/ml) for 48 h and
subsequently cell culture supernatants (ConASn) were collected.
Cells were grown in RPMI-1640 medium supplemented with 5%
fetal calf serum (FCS, PAA Laboratories). Astrocytes were isolated
from mixed glial cell cultures prepared from brains of newborn
AO or DA rats as previously described (McCarthy and de Vellis,
1980). They were grown in the culture medium supplemented with
4 g/l glucose and they were puriﬁed by repetition of trypsiniza-
tion (0.25% trypsin and 0.02% EDTA, both from Sigma–Aldrich)
and re-plating. The cells used in these experiments were obtained
after third passage and were >95% positive for glial ﬁbrilar acidic
protein (GFAP) and <3% positive for CD11b, as deduced by cytoﬂu-
orimetric analysis. Astrocytes were seeded at 1.5 × 105/ml/well of
24-well plates (Sarstedt,). ConASn, recombinant rat TNF (Peprotech,
Rocky Hill, NJ), recombinant rat IFN- (Sigma–Aldrich), recom-
binant mouse IL-17 (R&D Systems, Minneapolis, MN)  and a TNF
inhibitor etanercept (fusion protein of TNFRII and human IgG1)
(Amgen-Wyeth, Thousand Oaks, CA,) were used for treatment of
astrocytes.
ELISA
TNF concentration in cell culture supernatants and supernatants
of homogenates was determined by sandwich ELISA using Max-
iSorp plates (Nunc, Rochild, Denmark) and anti-cytokine paired
antibodies according to the manufacturer’s instructions (BD Bio-
sciences, San Diego, CA). Samples were analyzed in duplicates and
the results were calculated using standard curves made on the
basis of known concentrations of the recombinant rat cytokines
(Peprotech, Rocky Hill, NJ).
Immunoblot
Spinal cord homogenates were prepared in a lysis solution
(25 mM Tris HCl buffer pH 7.4, 1 mM EDTA-Na2, 150 mM NaCl,
0.1% SDS, 1% NP-40). Supernatants were collected after cen-
trifugation (16,000 × g, 20′) and protein concentration in the
supernatants was  measured by Lowry protein assay. The volume
of the supernatants containing 50 g of total proteins was  mixed
with appropriate volume of a gel-loading buffer (62.5 mM Tris–HCl
(pH 6.8, 2% w/v sodium dodecyl sulfate (SDS), 10% glycerol, 50 mM
dithiothreitol (DTT), 0.01% (w/v) bromophenol blue, 1 mM phenyl-
methylsulphonyl ﬂuoride (PMSF), 1 g/ml aprotinine, 2 mM EDTA).
The samples were electrophoresed on a 12% SDS-polyacrylamide
gel. The samples were electro-transferred to polyvinylidene diﬂuo-
ride membranes at 5 mA/cm2, using semi-dry blotting system
(Fastblot B43, Biorad, Muenchen, Germany). The blots were blocked
with 5% (w/v) bovine serum albumin in PBS 0.1% Tween-20 and
probed with speciﬁc antibodies to TNF (Abcam, Cambridge, UK
or Santa Cruz, Dallas, TX) and beta-Actin (Abcam, Cambridge, UK)
followed by incubation with secondary antibody at 1:10,000 dilu-
tion (ECL goat anti-rabbit or anti-mouse horseradish peroxidase
(HRP)-linked, GE Healthcare, Buckinghamshire, UK). Detection was
performed by the chemiluminescence (ECL, GE Healthcare) and
photographs were made by X-ray ﬁlms (Kodak, Rochester, NY).
Densitometry was  performed with Scion Image Alpha 4.0.3.2 (Scion
Corporation, Frederick, MD). Results are presented as relative
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Fig. 1. TNF mRNA expression in the spinal cords of AO and DA rats. RNA was obtained
from spinal cord homogenates (A), immune cells isolated from the spinal cords (B)
or CD4+ T cells puriﬁed from the immune cells (C) at the indicated time points
of  different phases of EAE in DA rats. Subsequently, real time RT-PCR was  per-
formed. The results are presented as mean + SD of values from at least 6 samples per
group obtained in at least 3 independent experiments. *p < 0.05 refers to statisticallyJ. Blazˇevski et al. / Immun
ensitometry values (RDV), i.e. ratio of TNF and beta-Actin bands
ensitometry values.
everse transcription – real time polymerase chain reaction
In order to determine cytokine gene expression real time PCR
as performed. Total RNA was isolated using a mi-Total RNA
solation Kit (Metabion, Martinsried, Germany) and reverse tran-
cribed using random hexamer primers and MMLV  (Moloney
urine Leukemia Virus) reverse transcriptase, according to the
anufacturer’s instructions (Fermentas, Vilnius, Lithuania). Pre-
ared cDNAs were ampliﬁed by using Maxima SYBR Green/ROX
PCR Master Mix  (Fermentas) according to the recommendations
f the manufacturer in a total volume of 20 l in an ABI PRISM
000 Sequence Detection System (Applied Biosystems, Foster City,
A). Thermocycler conditions comprised an initial step at 50 ◦C for
 min, followed by a step at 95 ◦C for 10 min  and a subsequent 2-step
CR program at 95 ◦C for 15 s and 60 ◦C for 60 s for 40 cycles. The
CR primers (Metabion) were as follows: -actin forward primer
′-GCT TCT TTG CAG CTC CTT CGT-3′; -actin reverse primer 5′-CCA
CG CAG CGA TAT CG-3′; TNF forward primer 5′-TCG AGT GAC AAG
CC GTA GC-3′; TNF reverse primer 5′-CTC AGC CAC TCC AGC TGC
C-3′; CXCL12 forward primer 5′-GAT TCT TTG AGA GCC ATG TC-3′;
XCL12 reverse primer 5′-GTC TGT TGT TGC TTT TCA GC-3′. Accu-
ulation of PCR products was detected in real time and the results
nalyzed with 7500 System Software (AB) and presented as 2−dCt,
Ct being the difference between Ct values of a gene of interest and
he endogenous control (-actin).
tatistical analysis
The results are presented as mean + SD of values obtained in
epeated experiments. A Student’s t test (two-tailed) was per-
ormed for statistical analysis of differences between two  groups.
NOVA followed by Tukey test was performed for comparison of
ean values of multiple groups. Pearson’s test was  used for the
orrelation analysis. A p value less than 0.05 was considered statis-
ically signiﬁcant.
esults
NF mRNA expression in spinal cords of DA rats and AO rats
TNF mRNA expression was determined in the CNS samples
f the immunized and non-immunized AO and DA rats. In DA
ats TNF expression increased in spinal cord homogenates after
mmunization, but this increase was not statistically signiﬁcant.
ctually, there was no signiﬁcant difference in TNF expression
n spinal cord homogenates of DA rats between any of the time
oints examined (Fig. 1A). On the contrary, in AO rats TNF mRNA
xpression was signiﬁcantly increased in spinal cord homogenates
pon immunization, reaching the highest values on 9–11 d.p.i.,
nd then signiﬁcantly decreased on 18–22 d.p.i. (Fig. 1A). When
he strains were compared, TNF expression in the homogenates
as consistently higher in AO than in DA rats, both in samples of
on-immunized animals and in samples obtained at the time of
nset and peak of EAE in DA rats (Fig. 1A). Similar results were
btained with immune cells isolated from spinal cords (isolates):
NF mRNA expression was signiﬁcantly higher in AO isolates than
n DA isolates on 12–15 d.p.i. and on 18–22 d.p.i. (Fig. 1B). Also,
NF mRNA expression was higher in CD4+ T cells puriﬁed from
he isolates of AO rats on 12–15 d.p.i. (Fig. 1C). Thus, relatively
igh mRNA expression of TNF is a characteristic of EAE-resistant
ats.signiﬁcant difference between AO and DA rats. #p < 0.05 refers to statistically sig-
niﬁcant difference to samples of non-immunized rats. “p < 0.05 refers to statistically
signiﬁcant difference to recovery.
TNF production in spinal cords of DA rats and AO rats
TNF concentration in supernatants of spinal cord homogenates
subjected to high speed centrifugation was  without signiﬁcant dif-
ference in AO and DA samples on 9–11 d.p.i. and on 12–15 d.p.i.
(Fig. 2A). Also, immunoblot of spinal cord homogenates have shown
that there is no difference in transmembrane (26 kD) or soluble
(17 kD) TNF isoform in samples of AO and DA rats at the time of
EAE peak in DA rats (Fig. 2B). Still, TNF level was higher in super-
natants of AO isolates than in corresponding DA samples on 12–15
d.p.i. (Fig. 2C). Thus, production of TNF was similar in EAE-resistant
and EAE-prone rats.
Correlation of TNF and CXCL12 mRNA expression in the CNS of AO
and DA rats
TNF and CXCL12 mRNA expression correlation was determined
in spinal cord homogenates of the immunized DA rats. Sam-
ples from non-immunized rats were included in the analysis, as
well. A strong positive correlation (r = 0.870, p < 0.01) between
expression of the two  genes was demonstrated in the spinal cord
homogenates (Fig. 3A). Accordingly, a strong positive correlation
between TNF and CXCL12 mRNA expression was observed in spinal
cord homogenates isolated from AO rats (r = 0.758, p < 0.01). This
result implied that there is a link between TNF and CXCL12 mRNA
expression regulation in the CNS during EAE.
TNF stimulates CXCL12 expression in astrocytes
Effects of TNF on CXCL12 expression in astrocytes were inves-
tigated. In order to mimic  neuroinﬂammation, astrocytes isolated
from DA rats were stimulated with IFN- and IL-17 and treated with
TNF. Concentrations of IFN- and IL-17 that were used in our exper-
iments have been previously shown to be effective in individual
or cooperative stimulation of astrocytes to produce inﬂamma-
tory mediators, e.g. nitric oxide (Trajkovic et al., 2001). However,
848 J. Blazˇevski et al. / Immunobiolo
Fig. 2. TNF production in the spinal cords of AO and DA rats. (A) Spinal cord
homogenates were centrifuged and supernatants were collected for testing by ELISA.
(B)  Relative expression of transmembrane and soluble TNF (TNFm and TNFs, respec-
tively) in spinal cord homogenates on 12–15 d.p.i. determined by immunoblot. A
representative blot showing 3 AO and 3 DA samples is also presented. Relative den-
sitometry value (RDV) is normalized to AO TNFm mean densitometric value that was
arbitrarily given value of 1. C) Immune cells isolated from spinal cords were grown
in  cell culture for 24 h. Cell-free supernatants were tested by ELISA. The results
are presented as mean + SD of values from at least 6 samples per group obtained
in  at least 3 independent experiments. *p < 0.05 refers to statistically signiﬁcant
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the CNS inﬂammation in EAE in mice (McCandless et al., 2006).
This data contributes to the understanding of the importance ofifference between AO and DA rats.
hey were not efﬁcient in inducing CXCL12 in astrocytes (Fig. 4A).
n the contrary, TNF induced CXCL12 gene expression in astro-
ytes on its own and in the presence of IFN- and IL-17 (Fig. 4A).
urther, DA astrocytes were treated with ConASn that contains var-
ous cytokines, including TNF (>200 pg/ml). In response to ConASn
XCL12 expression was markedly elevated in astrocytes, while an
nhibitor of TNF activity, etanercept signiﬁcantly reduced CXCL12
xpression in ConASn-stimulated astrocytes (Fig. 4B). Finally, in
rder to determine if the observed effect of TNF on CXCL12 mRNA
xpression in astrocytes was strain speciﬁc, astrocytes isolated
rom AO rats were treated with TNF. Here again, TNF alone or in
ooperation with IFN- and IL-17 stimulated CXCL12 expression
Fig. 4C). Thus, TNF is a potent stimulator of CXCL12 expression in
strocytes.gy 220 (2015) 845–850
Discussion
In the present paper, it is shown that relatively high CNS TNF
mRNA expression is a feature of EAE resistant AO rats. The observed
pattern of the CNS TNF expression in AO and DA rats is similar
to that previously observed for CXCL12 (Miljkovic´ et al., 2011a).
Furthermore, a strong positive correlation has been determined
between mRNA expression of TNF and CXCL12 in spinal cord
homogenates of AO and DA rats. Importantly, low expression of
TNF and CXCL12 coincides with high number of immune cells inﬁl-
trating the CNS in EAE-susceptible DA rats, while high expression
of these molecules concurs with low number of the inﬁltrating cells
in EAE-resistant AO rats (Miljkovic´ et al., 2011a). Thus, it could be
assumed that TNF induces CXCL12 that limits immune cell invasion
into the CNS. Indeed, TNF is shown able to induce and stimulate
CXCL12 expression in astrocytes that are important source of this
chemokine within the CNS.
TNF contributes to MS  pathogenesis through induction of
cytokine and chemokine expression in the CNS, disruption of
blood–brain barrier, promotion of inﬂammatory cell inﬁltration
and direct induction of neurodegeneration (Caminero et al. 2011;
Sibson et al., 2002; Rossi et al., 2014). However, it also pro-
motes remyelination and has neuroprotective effects (Taouﬁk
et al., 2008). The dual role of TNF in neuroinﬂammation can be
explained by divergent effects that this cytokine exerts through
TNFRI and TNFRII. For instance, it has been shown that TNFRI
(p55) is necessary for inﬁltration of immune cells into the CNS
parenchyma (Gimenez et al., 2006), while TNFRII (p75) is essen-
tial for engagement and induction of regulatory T cells (Tsakiri
et al., 2012). Accordingly, TNFRI−/− mice were partially protected
from MOG(35-55)-induced EAE, whereas TNFRII−/− mice exhib-
ited exacerbated EAE (Suvannavejh et al., 2000; Eugster et al., 1999).
As sTNF has higher afﬁnity for TNFRI, while tmTNF has higher afﬁn-
ity for TNFRII it is proposed that blockade of sTNF/TNFRI axis, while
preserving tmTNF/TNFRII axis might be a right approach for treat-
ment of MS  (Van Hauwermeiren et al., 2011). This idea is ﬁrmly
supported by the reports of beneﬁcial effects of a selective sTNF
blocker XPro1595, but not of a general TNF inhibitor etanercept in
EAE in mice (Brambilla et al., 2011; Taouﬁk et al., 2011). Still, we  did
not detect higher tmTNF or lower sTNF production in EAE-resistant
AO rats. This result suggests that potential beneﬁcial effects of TNF
in AO rats are not a consequence of elevated expression of tmTNF.
Importantly, although sTNF has been reportedly indicated as
a proinﬂammatory molecule in EAE and MS,  its positive effect
on CXCL12 expression in astrocytes has been observed in our
study. Inﬂuence of TNF on CXCL12 production in astrocytes was
not determined in our study. Still, our previous data implied
that CXCL12 production was  dominantly regulated at transcrip-
tional level within the CNS (Miljkovic´ et al., 2011a). In the same
paper CXCL12 was  identiﬁed as a key protective molecule in rat
EAE. Importantly, application of an inhibitor of CXCL12 activity –
AMD3100, to AO rats is one of the rare treatments that have been
efﬁcient in overcoming the resistance of these rats to EAE induction
(Miljkovic´ et al., 2011a). As astrocytes are among the principal pro-
ducers of this chemokine in neuroinﬂammation (Ambrosini et al.,
2005), our results about the positive inﬂuence of TNF on CXCL12
generation in astrocytes indicate that TNF could be an important
stimulator of CXCL12 expression in neuroinﬂammation. Besides
astrocytes, endothelial cells are the most prominent producers
of CXCL12 in the CNS (Momcilovic´ et al., 2012). As a matter of
fact, irregular CXCL12 expression in blood–brain barrier endothe-
lial cells was  shown responsible for initiation and propagation ofthe complex net of the CNS endothelial cell adhesion and chemo-
tactic molecule production in MS  and EAE (Engelhardt, 2008).
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A B
Fig. 3. Correlation between TNF and CXCL12 expression in spinal cord homogenates of rats. Spinal cords were isolated from non-immunized rats or from the immunized
rats  at the time of onset, peak and recovery in DA rats (n = 20, n = 5 for each time point). Correlation between expression of TNF and CXCL12 mRNA expression in DA (A) and
AO  (B) rats was  determined. Curves on the graphs represent trendlines of correlation.
Fig. 4. The inﬂuence of TNF on CXCL12 mRNA expression in astrocytes. Astrocytes were isolated from DA rats (A, B) or AO rats (C) and they were treated with TNF in the
absence  (medium) or presence of 10 ng/ml IFN- and 50 ng/ml IL-17 (A, C) or they were stimulated with ConASn (20%) in the absence or presence of etanercept (250 ng/ml)
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eB).  After 24 h of cultivation, RNA was isolated from the cells and real time RT-PCR w
efers  to statistically signiﬁcant difference in comparison to untreated cultures. #p
tanercept.
ndothelial cell regulation of T cell migration across the
lood–brain barrier is counteracted by locally produced TNF (Yang
t al., 2013). On the contrary, TNF could contribute to the regula-
ion through stimulation of CXCL12 expression in endothelial cells.
herefore, it would be important to determine the effect of TNF
n CXCL12 expression in the CNS endothelial cells. Importantly,
igh expression of TNF might be responsible for high expression
f CXCL12 in the CNS of EAE-resistant AO rats. It was previously
hown that CXCL12 expression is higher in AO rats only at the time
f peak, but not at the time of onset of EAE in DA rats (Miljkovic´
t al., 2011a). Accordingly, here it is presented that TNF production
y the immune cells isolated from spinal cord of the immunized rats
ollow the same time pattern. This pattern is not observed if total
NF release within the CNS is determined. Thus, it is tempting to
peculate that TNF produced by the inﬂammatory immune cells has
he major role in stimulation of CXCL12 expression within the CNS.
orthy of notion, other factors besides TNF determine level of this
hemokine in the inﬂamed CNS. We  have recently demonstrated
hat IL-10 stimulates CXCL12 expression in astrocytes (Blazˇevski
t al., 2013). Also, nitric oxide, which is abundantly produced in
A, but not AO rats CNS after EAE immunization seems to be a
ey inhibitor of CXCL12 expression in neuroinﬂammation (Petkovic´
t al., 2013).onclusions
It has been previously shown that CXCL12 and TGF- are amply
xpressed in the CNS of AO rats and that they could contribute to therformed. The results are presented as mean + SD from three experiments. *p < 0.05
 refers to statistically signiﬁcant difference in comparison to cultures treated with
resistance of these rats to EAE (Miljkovic´ et al., 2011a; Lukic et al.,
2001; Blazˇevski et al., 2013). Here, relatively high expression of TNF
in the CNS of AO rats, even when these animals are not immunized is
demonstrated. Also, the ability of TNF to induce CXCL12 expression
in the CNS is demonstrated. Thus, the present report adds TNF to
the list of potential candidate molecules contributing to resistance
of AO rats to EAE induction. In general, our data support a view of
beneﬁcial role of TNF in neuroinﬂammation.
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